BOND LABORATORIES, INC. Form 10-O August 12, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-Q

OUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES х **EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2011

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES 0 EXCHANGE ACT

For the transition period from N/A to N/A

Commission File No. 333-137170

BOND LABORATORIES, INC. (Name of small business issuer as specified in its charter)

Nevada

20-3464383

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

11011 Q Street Building A Suite 106 Omaha, NE 68137 (Address of principal executive offices)

> (402) 884-1894 (Issuer's telephone number)

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b–2 of the Exchange Act. (Check one):

Edgar Filing: BOND LABORATORIES, INC. - Form 10-Q

Large accelerated filer Non–Accelerated filer Accelerated filer " Small reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes "No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class Common stock, \$0.01 par value

••

••

Outstanding at August 15, 2011 72,824,496

BOND LABORATORIES, INC. INDEX TO FORM 10-Q FILING FOR THE THREE MONTHS ENDED JUNE 30, 2011

TABLE OF CONTENTS

PAGE

PART I - FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements	1
	Condensed Consolidated Balance Sheets	2
	Condensed Consolidated Statement of Operations	3
	Condensed Consolidated Statement of Cash Flows	4
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management Discussion & Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16
Item 4.	Controls and Procedures	17
PART II - OTHER INFORMATION		
Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 5.	Other information	19
Item 6.	Exhibits	19

CERTIFICATIONS

- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
- 32.2 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
- 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying reviewed interim consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2010. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the six months ended June 30, 2011 are not necessarily indicative of the results that can be expected for the year ending December 31, 2011.

-1-

BOND LABORATORIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	 (Unaudited)		D 1 11		
ASSETS:	June 30, 2011	L	December 31, 2010		
	2011		2010		
CURRENT ASSETS					
Cash	\$ 263,932	\$	445,662		
Accounts receivables - net	1,269,186		574,616		
Inventory	1,974,753		1,473,605		
Prepaid expenses and other current assets	53,156		54,045		
Total current assets	3,561,027		2,547,928		
PROPERTY AND EQUIPMENT, net	59,866		87,208		
Intangibles assets, net	1,586,489		1,696,363		
Deposits	3,783		3,783		
TOTAL ASSETS	\$ 5,211,165	\$	4,335,282		
LIABILITIES AND STOCKHOLDERS' EQUITY:					
CURRENT LIABILITIES:					
Accounts payable	\$ 1,124,034	\$	508,146		
Disputed accounts payables	-		113,299		
Accrued expenses and other liabilities	110,144		101,467		
Note payable	98,500		194,718		
Line of credit	437,089		437,089		
Total current liabilities	1,769,767		1,354,719		
TOTAL LIABILITIES	1,769,767		1,354,719		
CONTINGENCIES AND COMMITMENTS	-		-		
STOCKHOLDERS' EQUITY:					
Preferred stock Series B, \$.01 par value,					
1,000 shares					
authorized; 103.3 and 103.3 issued and					
outstanding of its					
10% Perpetual Preferred with a Stated Value					
of \$10,000 per					
share with a cumulative dividend of					
\$510,566 and \$436,188					
as of June 30, 2011 and December 31, 2010,					
respectively	510,567		436,189		
Preferred stock Series C, \$.01 par value, 500 shares					

Edgar Filing: BOND LABORATORIES, INC. - Form 10-Q

authorized; 125 and 125 issued and				
outstanding				
as of June 30, 2011 and December 31, 2010,				
respectively	1		1	
Common stock, \$.01 par value, 150,000,000				
shares authorized;				
72,824,496 and 72,198,246 issued and				
outstanding				
as of June 30, 2011 and December 31, 2010,				
respectively	728,245		721,982	
Additional paid-in capital	27,179,770		27,404,593	
Accumulated deficit	(24,977,185)	(25,582,201)
Total stockholders' equity	\$ 3,441,398		\$ 2,980,564	
TOTAL LIABILITIES AND				
STOCKHOLDERS' EQUITY	\$ 5,211,165		\$ 4,335,282	